Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Cancer Res. 2013 Jun 6;73(15):4697–4710. doi: 10.1158/0008-5472.CAN-13-0930

Figure 7. Expression of exogenous progesterone receptor in the stroma of PTENKO/Kras tumors shifted their biologic behavior from hormone refractory to hormone sensitive cancers.

Figure 7

(A) Experimental strategy for over-expression of PR in the stroma of PTENKO/Kras tumors. (B) Over expression of human PR in the stroma of PTENKO/Kras tumors facilitated tumor resolution in response to progesterone therapy. PTENKO/Kras tumors expressing GFP in the stroma were resistant to progesterone therapy (n=2) (a-c) and resembled placebo treated counterparts (n=2) (d-f). Tumors over-expressing stromal PR responded to progesterone (n=3) evidenced by formation of cysts attached to the kidney (g-i) compared to placebo (j-l) treated controls (n=3). Scale bars equal 100μm except where noted.